Tags

Type your tag names separated by a space and hit enter

Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study.
Acta Ophthalmol Scand. 2007 Sep; 85(6):618-22.AO

Abstract

PURPOSE

As advanced glycation endproducts (AGEs) and the vitreous body are both considered to be involved in the development of diabetic retinopathy and hydroimidazolone is one of the most prominent AGEs, we compared vitreous and serum hydroimidazolone in diabetes patients with proliferative diabetic retinopathy (PDR) to levels in non-diabetes controls, co-measuring vitreous albumin and vascular endothelial growth factor (VEGF).

METHODS

In a cross-sectional case-control study design, we used immunoassays to compare vitreous and serum hydroimidazolone and VEGF levels in 23 consecutive type 2 diabetes mellitus patients with a median known diabetes duration of 12 years (range 1-38 years) with those in 32 non-diabetes age-matched controls undergoing vitrectomy.

RESULTS

Vitreous hydroimidazolone was increased in the PDR group (median 1.3 U/ml, range 0.5-3.3 U/ml) compared with controls (median 0.8 U/ml, 0.5-2.5 U/ml) (p = 0.026). Hydroimidazolone levels in serum and vitreous correlated (r = 0.49, p = 0.019). In PDR, vitreous VEGF levels were increased (median 1600 pg/ml, range 20-14 700 pg/ml) compared with controls (median 7 pg/ml, range 2-500 pg/ml) (p < 0.001). Similarly, vitreous albumin concentration was increased in PDR (median 1.6 g/l, range 0.7-3.0 g/l) compared with controls (median 0.3 g/l, range 0.08-1.9 g/l) (p < 0.001). Albumin could not explain the differences in vitreous VEGF levels in a logistic regression analysis. No correlation was found between vitreous levels of VEGF and hydroimidazolone (r = 0.12, p = 0.59).

CONCLUSIONS

Increased vitreous hydroimidazolone is associated with diabetic retinopathy, possibly due to a blood-retinal barrier breakdown. Irrespective of origin, it may add to the ocular damage and needs further causal investigation. Increased VEGF in diabetic vitreous is probably of intraocular origin. It is not associated with vitreous hydroimidazolone.

Authors+Show Affiliations

Diabetes Research Centre, Aker and Ullevål University Hospitals, Ullevål University Hospital, Oslo, Norway. dag.fosmark@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17488318

Citation

Fosmark, Dag S., et al. "Increased Vitreous Levels of Hydroimidazolone in Type 2 Diabetes Patients Are Associated With Retinopathy: a Case-control Study." Acta Ophthalmologica Scandinavica, vol. 85, no. 6, 2007, pp. 618-22.
Fosmark DS, Bragadóttir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmol Scand. 2007;85(6):618-22.
Fosmark, D. S., Bragadóttir, R., Stene-Johansen, I., Berg, J. P., Berg, T. J., Lund, T., Sandvik, L., & Hanssen, K. F. (2007). Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmologica Scandinavica, 85(6), 618-22.
Fosmark DS, et al. Increased Vitreous Levels of Hydroimidazolone in Type 2 Diabetes Patients Are Associated With Retinopathy: a Case-control Study. Acta Ophthalmol Scand. 2007;85(6):618-22. PubMed PMID: 17488318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. AU - Fosmark,Dag S, AU - Bragadóttir,Ragnheidur, AU - Stene-Johansen,Ingar, AU - Berg,Jens P, AU - Berg,Tore J, AU - Lund,Terje, AU - Sandvik,Leiv, AU - Hanssen,Kristian F, Y1 - 2007/05/04/ PY - 2007/5/10/pubmed PY - 2007/10/24/medline PY - 2007/5/10/entrez SP - 618 EP - 22 JF - Acta ophthalmologica Scandinavica JO - Acta Ophthalmol Scand VL - 85 IS - 6 N2 - PURPOSE: As advanced glycation endproducts (AGEs) and the vitreous body are both considered to be involved in the development of diabetic retinopathy and hydroimidazolone is one of the most prominent AGEs, we compared vitreous and serum hydroimidazolone in diabetes patients with proliferative diabetic retinopathy (PDR) to levels in non-diabetes controls, co-measuring vitreous albumin and vascular endothelial growth factor (VEGF). METHODS: In a cross-sectional case-control study design, we used immunoassays to compare vitreous and serum hydroimidazolone and VEGF levels in 23 consecutive type 2 diabetes mellitus patients with a median known diabetes duration of 12 years (range 1-38 years) with those in 32 non-diabetes age-matched controls undergoing vitrectomy. RESULTS: Vitreous hydroimidazolone was increased in the PDR group (median 1.3 U/ml, range 0.5-3.3 U/ml) compared with controls (median 0.8 U/ml, 0.5-2.5 U/ml) (p = 0.026). Hydroimidazolone levels in serum and vitreous correlated (r = 0.49, p = 0.019). In PDR, vitreous VEGF levels were increased (median 1600 pg/ml, range 20-14 700 pg/ml) compared with controls (median 7 pg/ml, range 2-500 pg/ml) (p < 0.001). Similarly, vitreous albumin concentration was increased in PDR (median 1.6 g/l, range 0.7-3.0 g/l) compared with controls (median 0.3 g/l, range 0.08-1.9 g/l) (p < 0.001). Albumin could not explain the differences in vitreous VEGF levels in a logistic regression analysis. No correlation was found between vitreous levels of VEGF and hydroimidazolone (r = 0.12, p = 0.59). CONCLUSIONS: Increased vitreous hydroimidazolone is associated with diabetic retinopathy, possibly due to a blood-retinal barrier breakdown. Irrespective of origin, it may add to the ocular damage and needs further causal investigation. Increased VEGF in diabetic vitreous is probably of intraocular origin. It is not associated with vitreous hydroimidazolone. SN - 1395-3907 UR - https://www.unboundmedicine.com/medline/citation/17488318/Increased_vitreous_levels_of_hydroimidazolone_in_type_2_diabetes_patients_are_associated_with_retinopathy:_a_case_control_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1395-3907&amp;date=2007&amp;volume=85&amp;issue=6&amp;spage=618 DB - PRIME DP - Unbound Medicine ER -